Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In
  • Become a Member
  • MB Vision
  • Members
    • Become a Member
      • Types & Rates
    • Benefits
      • Savings and Rewards
    • Member News
    • Member Events
    • Career Center
    • Directory
    • Pay Company Dues
    • FAQs
  • Events
    • Upcoming
    • Types of Events
    • Sponsorship Opportunities
    • The State of Possible Conference
    • Align Summit
    • Member Events
  • Innovation
    • About
    • Drive
      • Application
      • Alumni
      • Partners – MassBio
      • Partners – SCbio
      • Get Involved
      • FAQs
    • CEO & Founder Link
    • Align Summit
    • Partnering
    • Sponsorship Opportunities
  • Savings
    • MassBioEdge
  • Conference Center
    • About MassBioHub
    • Packages & Special Offers
    • Venue Specifications
    • Reserve Today
  • Policy & Advocacy
    • Policy & Advocacy Efforts
    • Diversity, Equity, and Inclusion
      • DEI Report
      • Resource Center
      • Open Letter 2.0
      • Bioversity
    • Economic Development
      • BioReady® Communities
    • Workforce Development
      • Bioversity
    • Vision 2030
    • This is the place.
    • Industry Reports
      • Federal Actions Impact Report
      • Industry Snapshot
      • Biopharma Funding Report
      • DEI Report
      • MA Life Sciences Workforce
  • About
    • About MassBio
    • News & Thought Leadership
    • MB Vision
    • The Studio at Kendall Square
    • Sponsorship Opportunities
    • Staff
    • Board
    • Contact Us
  • Sign In
  • Become a Member
  • MB Vision
Open search form

Member Directory

Click to Open Main Menu

Ascidian Therapeutics

Life Sciences | Drug Development
Boston, MA Website https://twitter.com/AscidianTx LinkedIn

Overview

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With discovery, preclinical, and clinical programs in retinal, neurological, neuromuscular, and genetically defined diseases, Ascidian’s approach has the potential to treat patients with one dose of an RNA exon editor, opening new therapeutic possibilities for patients and their families who are seeking breakthroughs. For more information, visit www.ascidian.com.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • News & Thought Leadership
  • Pay Company Dues
  • Join Today
  • Contact
  • Privacy Policy
  • © 2025 All Rights Reserved